Abstract
Peyronie’s disease treatments is changing again due the interruption of Xiapex® distrubution in Europe. There are many reasons that can be referred to this event. In this editorial we would like to shed light on the current cost items relating to treatment with collagenase clostridium histolyticum (CCH). The inaccessibility of the drug has seen both an increase in surgery for the treatments of both PD and Dupuytren’s disease and an interruption of therapies in patients who had not completed their therapeutic cycle. Considering the aforementioned concerns, we would like to invite researchers dealing with PD to conduct studies with the available CCH products in collaboration with the drug companies in order to give again an efficacious treatment for PD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rohit A, Peter A, Paul A, Anja B, Christian D, Renate D, et al. Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren’s disease in 788 patients: the Austrian register. Arch Orthop Trauma Surg. 2019;139:1315–21.
Gelbard M, Goldstein I, Hellstrom WJG, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.
Salonia A, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, et al. European Association of Urology guidelines on sexual and reproductive health—2021 update: male sexual dysfunction. Eur Urol. 2021. https://doi.org/10.1016/j.eururo.2021.06.007.
Wymer K, Kohler T, Trost L. Comparative cost-effectiveness of surgery, collagenase clostridium histolyticum, and penile traction therapy in men with Peyronie’s disease in an era of effective clinical treatment. J Sex Med. 2019;16:1421–32.
Russo GI, Milenkovic U, Hellstrom W, Levine LA, Ralph D, Albersen M. Clinical efficacy of injection and mechanical therapy for Peyronie’s disease: a systematic review of the literature. Eur Urol. 2018;74:767–81.
Cocci A, Russo GI, Briganti A, Salonia A, Cacciamani G, Capece M, et al. Predictors of treatment success after collagenase Clostridium histolyticum injection for Peyronie’s disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study. BJU Int. 2018;122:680–7.
Author information
Authors and Affiliations
Contributions
The corresponding author confirm that he had full access to the data in the study and final responsibility for the decision to submit for publication. Study concept and design: AC and GIR. Acquisition of data: none. Analysis and interpretation of data: none. Drafting of the manuscript: AC and GIR. Critical revision of the manuscript for important intellectual content: JIMS, DR, RPD, ECS, NM, AC, GIR. Statistical analysis: none. Obtaining funding: none. Administrative, technical, or material support: none. Supervision: AC and GIR.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Cocci, A., Russo, G.I., Martinez-Salamanca, J.I. et al. Is there a line between ethics and market competition? Lights and shades of the withdrawal of collagenase treatment for Peyronie’s disease.
Int J Impot Res 34, 733–734 (2022). https://doi.org/10.1038/s41443-021-00469-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41443-021-00469-w
